A new antibody drug to restore the retina’s protective barrier
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models
This project tests a novel antibody designed to boost a natural signaling pathway to strengthen the retina’s protective barrier for people with retinal diseases that cause leaking or inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11249977 on NIH RePORTER |
What this research studies
Researchers are developing a first‑in‑class antibody that mimics natural Norrin/WNT signals to activate the FZD4/LRP5 pathway and support the blood‑retina barrier. Lab experiments in cells will check how the antibody causes receptor complexes to form and turn on protective beta‑catenin signaling. The team will also test the antibody in multiple mouse models that mimic different types of retinal barrier defects. The goal is to see whether the antibody can reduce leakage and inflammation and restore normal transport across the barrier as a step toward future patient trials.
Who could benefit from this research
Good fit: People with retinal conditions linked to blood‑retina barrier breakdown—such as diabetic retinopathy, wet age‑related macular degeneration, familial exudative vitreoretinopathy, or retinopathy of prematurity—would be the likely candidates for related future trials.
Not a fit: Patients whose vision loss is primarily due to long‑standing scarring, non‑barrier causes, or unrelated eye diseases may not benefit from this therapy.
Why it matters
Potential benefit: If successful, this approach could repair the blood‑retina barrier, reduce fluid leakage and inflammation, and help prevent vision loss in several retinal vascular diseases.
How similar studies have performed: Basic research has shown Norrin/WNT signaling helps maintain blood‑CNS barriers, but using a therapeutic FZD4/LRP5 agonist like this antibody is novel and largely untested in humans.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Junge, Harald — University of Minnesota
- Study coordinator: Junge, Harald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.